AH
Therapeutic Areas
Nanobiotix Pipeline
| Drug | Indication | Phase |
|---|---|---|
| NBTXR3 | Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) | Phase 3 |
| NBTXR3 + anti-PD1 | Head and Neck Cancer (recurrent/metastatic) | Phase 1 |
Leadership Team at Nanobiotix
LL
Laurent Levy
Co-Founder and Chief Executive Officer
BV
Bart Van Rhijn
Chief Financial Officer
GF
Gianfranco Fornari, M.D.
Chief Medical Officer
EB
Elsa Borghi, Ph.D.
Chief Regulatory Officer
CL
Christopher Leamon, Ph.D.
Chief Scientific Officer (Head of Research & Innovation)
SY
Sergey Yurasov
Chief Operating Officer
PM
Philippe Mauberna
Chairman of the Board of Directors
ES
Eliane Schutte
Board Member
SG
Sylvie Grégoire
Board Member
SS
Sarah Schlesinger, M.D.
Board Member